Organisation paid for research Program year 2025 Source: CMS Open Payments

Spectrum Clinical Research, Inc

Neither a doctor nor a teaching hospital

Research payments

$1,673,856

912 payments

Through program year 2025, Spectrum Clinical Research, Inc is reported as receiving $1,673,856 in research payments, across 912 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $152,585 4
2024 Research $33,100 8
2023 Research $328,663 137
2022 Research $280,549 170
2021 Research $362,438 217
2020 Research $396,379 295
2019 Research $120,143 81

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novo Nordisk AS $1,318,525 849 payments
  2. AstraZeneca Pharmaceuticals LP $152,585 4 payments
  3. AbbVie, Inc. $104,915 35 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $39,296 13 payments
  5. Novartis Pharmaceuticals Corporation $36,001 1 payment
  6. Amarin Pharma Inc. $12,385 1 payment
  7. Vifor (International) Ltd. $10,149 9 payments
Studies the money was for Research payments · program years 2019–2025
  1. Ex9536-4388 $1,300,503 736 payments
  2. M16-100 $104,915 35 payments
  3. a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure $95,678 1 payment
  4. A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event $38,037 1 payment
  5. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $36,001 1 payment
  6. BAY 1021189, A Phase 2b open-label clinical study to evaluate the tolerability and safety of an initiation dose of 5 mg of Vericiguat in participants with chronic heart failure with reduced ejection fraction $28,130 6 payments
  7. A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event $18,299 1 payment
  8. Nn9535-4533 $18,022 113 payments
  9. A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the effect of AMR101 on Cardiovascular Heath and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardio $12,385 1 payment
  10. BAY94-8862 LCM HFmr/pEF (EF 40%) $11,166 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record